Literature DB >> 7530749

Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule.

T Takeshita1, H Takahashi, S Kozlowski, J D Ahlers, C D Pendleton, R L Moore, Y Nakagawa, K Yokomuro, B S Fox, D H Margulies.   

Abstract

Although several peptides have been found to bind to both class I and class II molecules, the basis for this binding of the same peptide to two classes of MHC molecules has not been compared previously. We have analyzed one such peptide, P18 from the V3 loop of HIV-1 gp160, which we have previously shown to be recognized by CD8+ CTL with the class I molecule H-2Dd, and by CD4+ Th cells with the class II molecule I-Ad. With the use of truncated and substituted peptides, we found that the minimal core peptides are very similar, that the residues required for class I binding precisely fit the recently identified consensus motif for peptides binding to Dd (XGPX[R/K/H]XXX(X) [L/I/F]), and that at least three of the same residues are involved in binding to class II I-Ad. In addition, several of the same residues are involved in TCR interaction when the peptide is presented by class I and class II molecules. Modeling shows results to be consistent with the crystal structure of a peptide-class II MHC complex. Thus, the recognition of this versatile peptide by CD4+ Th cells with class II MHC molecules and by CD8+ cytotoxic T cells with class I MHC molecules is remarkably similar in both the core peptide used and the role of different residues in the ternary complex.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7530749

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  25 in total

1.  Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity.

Authors:  Y Lu; R Friedman; N Kushner; A Doling; L Thomas; N Touzjian; M Starnbach; J Lieberman
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

2.  Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector.

Authors:  J C Ramírez; M M Gherardi; D Rodríguez; M Esteban
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

3.  Coadministration of HIV vaccine vectors with vaccinia viruses expressing IL-15 but not IL-2 induces long-lasting cellular immunity.

Authors:  SangKon Oh; Jay A Berzofsky; Donald S Burke; Thomas A Waldmann; Liyanage P Perera
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-07       Impact factor: 11.205

4.  A push-pull approach to maximize vaccine efficacy: abrogating suppression with an IL-13 inhibitor while augmenting help with granulocyte/macrophage colony-stimulating factor and CD40L.

Authors:  Jeffrey D Ahlers; Igor M Belyakov; Masaki Terabe; Rima Koka; Debra D Donaldson; Elaine K Thomas; Jay A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  2002-09-13       Impact factor: 11.205

5.  Identification of an immunodominant mouse minor histocompatibility antigen (MiHA). T cell response to a single dominant MiHA causes graft-versus-host disease.

Authors:  C Perreault; J Jutras; D C Roy; J G Filep; S Brochu
Journal:  J Clin Invest       Date:  1996-08-01       Impact factor: 14.808

6.  Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein.

Authors:  T J Goletz; K R Klimpel; N Arora; S H Leppla; J M Keith; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

7.  Suppression of major histocompatibility complex class II-associated invariant chain enhances the potency of an HIV gp120 DNA vaccine.

Authors:  Xueqing Lu; Shuzhen Wu; Catherine E Blackwell; Robert E Humphreys; Eric von Hofe; Minzhen Xu
Journal:  Immunology       Date:  2006-11-20       Impact factor: 7.397

8.  Molecular analysis of TCR and peptide/MHC interaction using P18-I10-derived peptides with a single D-amino acid substitution.

Authors:  Yohko Nakagawa; Hiroto Kikuchi; Hidemi Takahashi
Journal:  Biophys J       Date:  2007-01-05       Impact factor: 4.033

9.  Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy.

Authors:  M A Alexander-Miller; G R Leggatt; J A Berzofsky
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

10.  The use of fluorescent target arrays for assessment of T cell responses in vivo.

Authors:  Benjamin J C Quah; Danushka K Wijesundara; Charani Ranasinghe; Christopher R Parish
Journal:  J Vis Exp       Date:  2014-06-19       Impact factor: 1.355

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.